Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.53 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400213 | 1.00 | GAA (0.54) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL6106268 | 1.00 | GAA (0.54) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL11267920 | 0.79 | PLA2G10 (0.60) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL20516445 | 0.79 | GAA (0.54) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL12408230 | 0.79 | PLA2G10 (0.60) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL20516443 | 0.79 | GAA (0.54) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL11398860 | 0.77 | GAA (0.74) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL11270312 | 0.77 | GAA (0.74) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL6625348 | 0.77 | CYP2C19 (0.44) | GAACYP3A4CYP2C19POLBCYP1A2 | |
| SCHEMBL6399098 | 0.77 | HDAC1 (0.49) | GAACYP3A4CYP2C19POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | GAA 1100/4885CYP3A4 666/4885CYP2C19 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.